The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis.
The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis.
复制标题
免疫相关不良事件与接受免疫治疗的实体癌患者预后之间的关联：系统评价和荟萃分析
DOI：
10.1177/1758835920980546
复制
发表时间：
2020
影响因子：
4.9
通讯作者：
Cao D
中科院分区：
文献类型：
--
作者：
Xu H;Xu X;Ge W;Lei J;Cao D
背景：免疫相关不良事件（irAEs）在免疫检查点抑制剂（ICI）治疗期间很常见，据报道与良好的生存率相关。本研究评估了irae的发病时间与接受ICIs治疗的癌症患者的生存之间的关系。方法：系统检索PubMed、Embase和Cochrane图书馆等数据库，检索评估ICIs癌症患者irae与生存关系的临床研究。使用RevMan 5.3计算治疗反应的总有效率、总生存期（OS）和无进展生存期（PFS）的风险比（HR）。根据癌症类型，ICIs类型，区域，特异性irae进行亚组分析。结果：共纳入34项研究。有irAEs的癌症患者的OS和PFS的hr为0.57[95%可信区间（CI）： 0.44, 0.74；p < 0.0001]和0.50 （95% CI: 0.37, 0.67; p < 0.00001）。与没有irAEs的癌症患者相比，irAEs患者总体缓解的优势比为4.72 （95% CI: 3.48, 6.40; p < 0.00001）。亚组分析表明，irAEs的预后作用与癌症类型和地区有关，而与irAEs类型无关。OS的里程碑分析显示，irAEs对CI治疗的癌症患者的OS存在非比例（早期）影响（里程碑>12周，HROS = 1.08; 95% CI: 0.89, 1.30; p = 0.46）。结论：我们的研究结果表明，irae的发生可能是接受ICIs治疗的癌症患者的预后因素。
Background: Immune-related adverse events (irAEs) are common during immune checkpoint inhibitor (ICI) treatment and reported to be associated with good survival. This study evaluated the association between onset timing of irAEs and survival of cancer patients treated with ICIs. Methods: Databases including PubMed, Embase, and the Cochrane library were systematically searched to retrieve clinical studies assessing the relationship between irAEs and survival in cancer patients with ICIs. The overall response rate for treatment response and hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were calculated using RevMan 5.3. Subgroup analysis in terms of cancer type, ICIs type, region, specific irAEs, accordingly. Results: A total of 34 studies were included. The HRs for OS and PFS in cancer patients with versus without irAEs were 0.57 [95% confidence interval (CI): 0.44, 0.74; p < 0.0001], and 0.50 (95% CI: 0.37, 0.67; p < 0.00001), respectively. The odds ratio for overall response in cancer patients with irAEs was 4.72 (95% CI: 3.48, 6.40; p < 0.00001) compared with those without irAEs. Subgroup analyses suggested that the prognostic role of irAEs was associated with cancer types and region, but not irAEs types. The landmark analysis of OS revealed that there is a non-proportional (early) effect of irAEs on OS in ICI-treated cancer patients (landmark >12 weeks, HROS = 1.08; 95% CI: 0.89, 1.30; p = 0.46). Conclusion: Our findings suggest that the occurrence of irAEs could be a prognostic factor for cancer patients who were treated with ICIs.
登录
查看更多内容
影响因子：
3.7
作者：
Dumenil C;Massiani MA;Dumoulin J;Giraud V;Labrune S;Chinet T;Giroux Leprieur E
通讯作者：
Giroux Leprieur E
影响因子：
3.4
作者：
Fujii T;Colen RR;Bilen MA;Hess KR;Hajjar J;Suarez-Almazor ME;Alshawa A;Hong DS;Tsimberidou A;Janku F;Gong J;Stephen B;Subbiah V;Piha-Paul SA;Fu S;Sharma P;Mendoza T;Patel A;Thirumurthi S;Sheshadri A;Meric-Bernstam F;Naing A
通讯作者：
Naing A
影响因子：
10.9
作者：
Hua, Camille;Boussemart, Lise;Robert, Caroline
通讯作者：
Robert, Caroline
免疫检查点抑制剂与化疗治疗晚期非小细胞肺癌的对比分析：随机对照试验的荟萃分析
影响因子：
1.6
作者：
Khan M;Lin J;Liao G;Tian Y;Liang Y;Li R;Liu M;Yuan Y
通讯作者：
Yuan Y
影响因子：
7.2
作者：
Kim, Hye In;Kim, Mijin;Kim, Tae Hyuk
通讯作者：
Kim, Tae Hyuk